GNFT
Price:
$4.2
Market Cap:
$200.94M
Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company's products include Elafibranor, which is in Phase 3 clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; GNS561, which is in Phase 1b/2 trial to treat patients with cholangiocarcinoma (CCA); and Nitazoxanide, which is in Phase 1 trial to treat acute-on-chronic liver failure. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic ...[Read more]
Industry
Biotechnology
IPO Date
2019-03-27
Stock Exchange
NASDAQ
Ticker
GNFT
According to Genfit S.A.’s latest financial reports and current stock price. The company's current Enterprise Value is 207.10M. This represents a change of 71.97% compared to the average of 120.42M of the last 4 quarters.
The mean historical Enterprise Value of Genfit S.A. over the last ten years is 327.89M. The current 207.10M Enterprise Value has changed 6.22% with respect to the historical average. Over the past ten years (40 quarters), GNFT's Enterprise Value was at its highest in in the December 2019 quarter at 595.57M. The Enterprise Value was at its lowest in in the March 2012 quarter at 0.
Average
327.89M
Median
373.87M
Minimum
12.20M
Maximum
564.88M
Discovering the peaks and valleys of Genfit S.A. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 1.07%
Maximum Annual Enterprise Value = 564.88M
Minimum Annual Increase = -92.71%
Minimum Annual Enterprise Value = 12.20M
Year | Enterprise Value | Change |
---|---|---|
2023 | 165.50M | 15.79% |
2022 | 142.93M | 1.07% |
2021 | 12.20M | -92.71% |
2020 | 167.27M | -70.30% |
2019 | 563.22M | -0.29% |
2018 | 564.88M | 21.38% |
2017 | 465.38M | 13.84% |
2016 | 408.81M | -9.10% |
2015 | 449.75M | 32.70% |
2014 | 338.92M | 13.26% |
The current Enterprise Value of Genfit S.A. (GNFT) is greater than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
106.88M
5-year avg
210.22M
10-year avg
327.89M
Genfit S.A.’s Enterprise Value is greater than Cyteir Therapeutics, Inc. (-20511738.00), greater than ERYTECH Pharma S.A. (20.24M), greater than Eliem Therapeutics, Inc. (119.64M), greater than HCW Biologics Inc. (34.47M), greater than Molecular Partners AG (130.63M), greater than MediciNova, Inc. (-41974173594.00), greater than Anebulo Pharmaceuticals, Inc. (36.46M), greater than Champions Oncology, Inc. (66.07M), less than Keros Therapeutics, Inc. (1.75B), less than Janux Therapeutics, Inc. (2.64B), greater than Fennec Pharmaceuticals Inc. (105.60M), less than Edgewise Therapeutics, Inc. (3.01B), less than Harmony Biosciences Holdings, Inc. (1.74B), greater than Aerovate Therapeutics, Inc. (46.23M), greater than Adagene Inc. (22.22M), greater than Acrivon Therapeutics, Inc. Common Stock (163.47M), less than Rezolute, Inc. (276.11M), greater than AN2 Therapeutics, Inc. (6.48M),
Company | Enterprise Value | Market cap |
---|---|---|
-20511738.00 | $108.71M | |
20.24M | $47.38M | |
119.64M | $342.68M | |
34.47M | $29.12M | |
130.63M | $216.81M | |
-41974173594.00 | $104.47M | |
36.46M | $37.86M | |
66.07M | $61.85M | |
1.75B | $2.27B | |
2.64B | $2.64B | |
105.60M | $145.92M | |
3.01B | $3.05B | |
1.74B | $1.94B | |
46.23M | $76.81M | |
22.22M | $97.11M | |
163.47M | $202.87M | |
276.11M | $284.50M | |
6.48M | $39.99M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Genfit S.A. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Genfit S.A. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is Genfit S.A.'s Enterprise Value?
What is the highest Enterprise Value for Genfit S.A. (GNFT)?
What is the 3-year average Enterprise Value for Genfit S.A. (GNFT)?
What is the 5-year average Enterprise Value for Genfit S.A. (GNFT)?
How does the current Enterprise Value for Genfit S.A. (GNFT) compare to its historical average?